GH Research PLC Ordinary Shares (GHRS) is a publicly traded Healthcare sector company. As of July 27, 2026, GHRS trades at $27.28 with a market cap of $1.87B and a P/E ratio of 0.00. GHRS moved -0.80% today. Year to date, GHRS is +118.24%; over the trailing twelve months it is +88.27%. Its 52-week range spans $6.72 to $31.00. Analyst consensus is strong buy with an average price target of $41.67. Rallies surfaces GHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Helus Pharma HLP003 Phase 3 Enrollment Hits 86%, On Track for Q4 2026 Data: Helus Pharma’s APPROACH Phase 3 trial of HLP003 for adjunctive major depressive disorder has surpassed 86% enrollment, maintaining schedule for a Q4 2026 topline data readout. Previous Phase 2 results reported a 23-point average reduction on the MADRS scale at 12 months, with response rates reaching 100% and 71% remission.
| Metric | Value |
|---|---|
| Price | $27.28 |
| Market Cap | $1.87B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.00 |
| 52-Week Low | $6.72 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
7 analysts cover GHRS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.67.